Who is sponsoring NCT01280188?

NCT01280188 is sponsored by Ferring Pharmaceuticals.

What drugs are being tested in NCT01280188?

Interventions in NCT01280188: Desmopressin Oral Melt, Desmopressin intranasal.

What condition does NCT01280188 study?

NCT01280188 studies Central Diabetes Insipidus.

Is NCT01280188 still recruiting?

NCT01280188 is currently completed. Last updated 10 August 2012.

Last reviewed 2012-08-10 · How we verify

NCT01280188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients

Completed Phase 3 Last updated 10 August 2012

What this trial tests

Phase 3 trial testing Desmopressin Oral Melt in Central Diabetes Insipidus in 20 participants. Completed in 1 August 2012.

Timeline

1 January 2011

Primary endpoint
1 August 2011

1 August 2012

Quick facts

Lead sponsor	Ferring Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2011
Primary completion	1 August 2011
Estimated completion	1 August 2012
Sites	5 locations across Japan

Drugs / interventions tested

Desmopressin Oral Melt
Desmopressin intranasal — full drug profile →

Conditions studied

Central Diabetes Insipidus — all drugs for Central Diabetes Insipidus →

Sponsor

Ferring Pharmaceuticals — full company profile →

Who can join

Adults 6 to 75, any sex, with Central Diabetes Insipidus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from Baseline in 24-hour Urine Volume
Time frame: Day 0, Week 4

Sponsor's own description

This is an open-label dose-titration study in Japanese Central Diabetes Insipidus (CDI) patients designed to demonstrate the efficacy and safety of orally-disintegrating tablet of desmopressin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ferring Pharmaceuticals trials

Trials by the same sponsor.

NCT07152730 — A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump · Phase 1 · withdrawn
NCT07029451 — To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt · recruiting
NCT06668493 — Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis · Phase 1, PHASE2 · recruiting
NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01280188 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ferring Pharmaceuticals
Last refreshed: 10 August 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01280188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing